Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients

22 May 2008

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glutathione Transferases and Polymorphisms
Share to Pharmacogenetics and Drug Metabolism
Share to Rheumatoid Arthritis Research and Therapies

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 18496682
DOI: 10.1007/s00228-008-0498-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patientsPMID 18496682Read ↗

Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritisSemantic proximity Read ↗

Genetic polymorphisms in metabolic pathways of leflunomide in the treatment of rheumatoid arthritis.Semantic proximity Read ↗

Genetic polymorphisms affect efficacy and adverse drug reactions of DMARDs in rheumatoid arthritis.Semantic proximity Read ↗

Frequency and impact of DHODH, ABCG2 and CYP2C19 SNPs on the therapeutic efficacy, tolerability and toxicity of leflunomide.Semantic proximity Read ↗

Association between SLCO1A2 genetic variation and methotrexate toxicity in human rheumatoid arthritis treatment.Semantic proximity Read ↗

Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis.Semantic proximity Read ↗

Prediction by pharmacogenetics of safety and efficacy of non-steroidal anti- inflammatory drugs: a review.Semantic proximity Read ↗

Polymorphism of human CYP2D genes involved in drug metabolism: possible relationship to individual cancer risk.Semantic proximity Read ↗

Are gene polymorphisms related to adverse events of methotrexate in patients with rheumatoid arthritis? A retrospective cohort study based on an updated meta-analysisSemantic proximity Read ↗

The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide.Semantic proximity Read ↗

Polymorphisms and pharmacogenomics for the toxicity of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic review and meta-analysis.Semantic proximity Read ↗

Relationship of Cytochrome P450 Gene Polymorphisms With Blood Concentration of Hydroxychloroquine and Its Metabolites and Adverse Drug ReactionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.